Alexion, Dicerna Launch $637M+ RNAi Collaboration in Complement-Mediated Diseases

Alexion Pharmaceuticals will apply Dicerna Pharmaceuticals’ GalXC™ platform to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases, through a collaboration that could generate more than $637 million for Dicerna, the companies said.The companies’ agreement gives Alexion exclusive worldwide licenses, plus development and commercial rights, to two Dicerna preclinical, subcutaneously-delivered GalXC RNAi molecules. Alexion and Dicerna agreed to p